The scientific and technological advancement have paved the way for several therapeutic antibodies in the management of cancer.
The scientific and technological advancement have paved the way for several therapeutic antibodies in the management of cancer. Therapeutic antibodies are immunoglobulin proteins which bind to specific antigens. These are unique in their ability to directly kill tumor cells while simultaneously engaging the host immune system to develop long-lasting effector response against the cancer cell. In recent times, multispecific antibodies have entered the market which has the ability to bind to two or more different antigens simultaneously, thus targeting the multifactorial nature of the disease.
Presently, only four bispecific antibodies including Blincyto, Hemlibra, Rybrevant, and Vabsymo have entered the market which has shown response in the market. The high adoption rates in the global market has further surged the research and development activities in this domain. For instance, Janssen Pharmaceutical has recently submitted biologics license application to the FDA for teclistamab as treatment of patients with relapsed or refractory multiple myeloma. Teclistamab is a novel, off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3.
Global Trispecific Antibody Market Opportunity And Clinical Trials Insight 2028 Report Analysis and Data Highlights:
- Research Methodology
- Global Market Analysis
- Global Trispecific Antibody Market Opportunity Assessment: > USD 2 Billion
- US To Dominate Trispecific Antibodies Market: >70%
- Market and Drug Sales Insight 2024 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
- Key Market Dynamics
- Competitor Landscape
Download Report:
Global Bispecific Antibody Market Insight 2028 Report Highlights:
- Research Methodology
- Global and Regional Market Analysis
- Global Bispecific Antibody Market Opportunity Assessment: > USD 20 Billion
- Market Sales Insight 2020 Till 2028
- Approved Drug Sales Insight Till Dec 2021(Updated Every Quarter)
- Approved Drug Sales Forecast Till 2028
- Approved Drug In Market: 4 Drugs
- Approved Bispecific Antibody Drug Patent, Price and Sales insight 2020 Till 2028
- Future Market Assessment By Indication Till 2028
- Ongoing Clinical Trials Assessment by Status, Phase and Region
Download Report:
In contrast the trispecific antibodies are mainly confined to early stages of clinical trials. The pipeline of trispecific antibody is highly crowded competitive and consists of several potential candidates including GTB3550, GTB4550, HPN217, NM21 -1480, SAR443216, and others. Recently in 2021, US FDA has granted orphan drug designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) developed by Harpoon Therapeutics which targets B-cell maturation antigen (BCMA). The FDA orphan designation program provides several incentives in terms of tax relaxation, patent exclusivity, rapid approval, and others which further increase the competition among pharmaceutical sectors.
The encouraging response of multispecific antibodies has gained significant investment from pharmaceutical companies in last few years. Apart from this, the companies have also adopted strategic alliances including partnerships, mergers, collaboration, or acquisitions to maintain their position in market. For instance in 2022, BioNtech and Crescendo Biologics announced that they have entered a multi-target discovery collaboration to develop novel immunotherapies for the treatment of patients with cancer and other diseases. In addition, Shanghai Junshi Bioscience and DotBio also entered into collaboration to develop next generation antibody therapies. Apart from this, Molecular Partners collaborated with University of Bern to advance the development of the Company’s wholly owned acute myeloid leukemia (AML) candidate, MP0533, into the clinic. MP0533 is a DARPin designed to engage CD3 on T cells and target AML cells by the tumor associated antigens (TAAs) CD33, CD123 and CD70. These rising trends in the pharmaceutical market suggests promising future of multispecific antibodies in the management of various chronic diseases.
Further, the advancements of genomics research and development activities and the emergence of technologically advanced genetic platforms, such as the next generation sequencing, have contributed significantly to the market and helped the existing companies in the global multispecific antibodies. The emergence of advanced technology and the launch of innovative products in the biotechnology field, and the growth in economy in developed and developing countries are also surging the demand of multispecific antibody.
It is estimated that more than 1500 clinical trials are ongoing in global multispecific antibody market, among which majority of clinical trials are evaluating their role in the management of cancer. Further, it is analyzed that around 4-7 multispecific antibodies will gain entry into the market by 2023. As per our analysis, the global multispecific antibody market is expected to get double in next 5 years and will surpass US$ 20 Billion by 2028. Our report provides comprehensive analysis on commercial information of available multispecific antibodies. Further, in-depth information on ongoing clinical trials and trends boosting the growth of market during the forecast period is also mentioned in report.
For More Information Related To Report Contact:
Neeraj Chawla
Research Head
Kuick Research
+919810410366